Actinium制药公司ATNM-400耐受性良好,有效剂量下未观察到体内毒性

美股速递
Apr 22

Actinium Pharmaceuticals公司宣布,其候选药物ATNM-400在有效剂量水平下展现出良好的耐受性特征。最新研究数据显示,该药物在实验过程中未引发任何体内毒性反应。这一积极结果为进一步临床开发奠定了坚实基础,表明ATNM-400在治疗窗内具有理想的安全性特征。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10